EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial

Gregory D. Lewis, Nora K. Horick, Fabely Moreno, Kenneth Lim, Diane Cocca-Spofford, Takenori Ikoma, Paridhi Gupta, Carly Camphausen, Laura Caccamo, Charounipha Soydara, Shaina McGinnis, Chloe Newlands, Skyler Williams, Alexandra Minasian, Nicholas Iskenderian, Isabela Landsteiner, Bhavani Iyer, Justin Joseph, Alvaro Delgado, Helena Tattersfield, Elizabeth Moore, Veronica Platt, Sujin Lee, Rajeev Malhotra

Circulation · 2026-11-08

DOI: 10.1161/circulationaha.126.084009 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND: Iron deficiency is present in >50% of patients with heart failure with preserved ejection fraction and is associated with reduced exercise capacity and survival. Whether iron repletion improves exercise capacity as objectively measured by peak oxygen uptake ( V ˙ o 2 ) is unknown. The IRONMET-HFpEF trial (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in HFpEF) sought to determine whether ferric derisomaltose (FDI) compared with placebo improves peak V ˙ o 2 in heart failure with preserved ejection fraction with iron deficiency. METHODS: This was a double-blind, placebo-controlled randomized clinical trial of patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →